In focus · trending topic

Elite Pharmaceuticals

52 stories · following the connections

Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study for Reformulated SequestOx™

By Nasdaq OMXMar 13, 2017, 12:00 PM UTC

Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017

By Nasdaq OMXFeb 9, 2017, 9:34 PM UTC

Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017

By Nasdaq OMXFeb 7, 2017, 1:01 PM UTC

Elite Reports On SequestOx™ FDA End-of-Review Meeting

By Nasdaq OMXJan 23, 2017, 1:19 PM UTC

Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®

By Nasdaq OMXJan 17, 2017, 1:00 PM UTC

Elite Provides Update on SequestOx™ New Drug Application

By Nasdaq OMXDec 22, 2016, 5:32 PM UTC

Elite Announces Development and License Agreement with SunGen Pharma LLC

By Nasdaq OMXAug 29, 2016, 12:00 PM UTC

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2017 and Provides Conference Call Information

By Nasdaq OMXAug 9, 2016, 8:20 PM UTC